https://www.live-feeds.com/feed/astrazeneca-readies-new-portfolio-of-targeted-cancer-therapiesContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/astrazeneca-readies-new-portfolio-of-targeted-cancer-therapieshttps://www.live-feeds.com/feed/astrazeneca-readies-new-portfolio-of-targeted-cancer-therapies#u163293Fri, 30 Oct 2026 08:52:05 +0000AstraZeneca is preparing to submit its first targeted cancer drug from a new portfolio for regulatory approval. The company showcased advances across its cancer portfolio at the European Society for Medical Oncology Congress in Madrid, presenting data that included late-stage trial results for a stomach cancer drug. According to trial data, the experimental drug extended overall survival and doubled survival time in certain CLDN 18.2-positive gastric cancer patients. Company executives maintained that the phase 3 antibody-drug conjugate data remains robust enough for regulators despite a progr